Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen DC Vaccine for Refractory Lung Cancer
NCT03871205Phase 1Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial in non-small cell lung carcinoma (NSCLC) and Small Cell Lung Cancer (SCLC), sponsored by Shenzhen People's Hospital. Primary endpoints: Treatment-Emergent Adverse Events and Immunogenicity of neoantigen-primed DC Vaccines. Status: unknown.
02
Conditions
non-small cell lung carcinoma (NSCLC)Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT03871205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871205.